// App-Quantinova.ai

P-112 : HGCSG1801: A phase II trial of 2nd-line FOLFIRI plus aflibercept in patients with metastatic colorectal cancer refractory to anti-EGFR antibody

Researchers

Presenter

  • Y. Shindo

Principal Investigators

  • S. Yuki

  • Y. Kawamoto

  • O. Muto

  • M. Dazai

  • K. Harada

  • Y. Kobayashi

  • S. Sogabe

  • M. Katagiri

  • M. Kotaka

  • M. Nakamura

  • K. Hatanaka

  • A. Ishiguro

  • Y. Tsuji

  • T. Kobayashi

  • M. Tateyama

  • Y. Sasaki

  • T. Sasaki

  • R. Takagi

  • Y. Sakata

  • Y. Komatsu

Medical Centers

  • Department of Gastroenterological Surgery, Nakadori General Hospital, Akita, Japan

  • Cancer Center, Hokkaido University Hospital, Sapporo, Japan

  • Department of Gastroenterology and Hepatology, Hokkaido University Hospital, japan, Sapporo, Japan

  • Department of Medical Oncology, Japanese Red Cross Akita Hospital, Akita, Japan

  • Department of Gastroenterology, Sapporo Medical Center NTT EC, Sapporo, Japan

  • Department of Medical Oncology, KKR Sapporo Medical Center, Sapporo, Japan

  • Department of Gastroenterology, Sapporo Hokuyu Hospital, Sapporo, Japan

  • Kohnan Hospital, Kobe, Japan

  • Department of Medical Oncology,Osaki Citizen Hospital, Osaki-Shi, Japan

  • Department of Gastroenterology, Ogaki Municipal Hospital, Ogaki, Japan

  • Department of Medical Oncology, Keiyukai Sapporo Hospital, Sapporo, Japan

  • Department of Medical Oncology, Keiyukai Sapporo Hospital, Sapporo, Japan

  • Department of Internal Medicine, Tomakomai Nisshou Hospital, Tomakomai, Japan

  • Department of Medical Oncology, Hakodate Central General Hospital, Hakodate, Japan

  • Department of Internal Medicine, Hokkaido Gastroenterology Hospital, Sapporo, Japan

  • Department of Clinical Research and Medical Innovation Center, Hokkaido University Hospital, Sapporo, Japan

  • Misawa City Hospital, Misawa, Japan

Locations

  • Japan

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Colorectal Cancer

  • Gastric Cancer

  • Brain metastasis

  • Venous thrombosis

  • Hypertension

  • Solid malignancies

Biomarkers

  • B-Raf proto-oncogene, serine/threonine kinase

  • UDP glucuronosyltransferase family 1 member A1

Drug/Treatment

  • L-leucovorin

  • Aflibercept

  • Oxaliplatin

  • Irinotecan

  • leucovorin

  • FOLFIRI

  • Adrucil injection

Outcome

  • N/A

Study Design

  • Randomized

  • Single Arm

  • Multicenteric

  • Prospective

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved